Bob G Gower bought $44k of ENSC
director at Ensysce Biosciences, Inc.. 90,287 shares at an average of $0.49, traded Mar 2, 2023, filed Mar 6, 2023.
Score components
- +15RoleDirector
- +6Trade size$44k at market
- +3Relative to holdingsHoldings up 8%
- +8Price context98% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying3 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-23-006786, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 2, 2023 | POpen-market purchase Common Stock | +90,287 | $0.49 | $44k | 1,222,682 | Mar 6, 2023 |
Related signals
Other insiders at Ensysce Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 42Moderate | ENSCbuy Ensysce Biosciences, Inc. | Bob G Gower director | $444k 908,614 shares | first purchase | |
| 60Notable | ENSCbuy Ensysce Biosciences, Inc. | Bob G Gower director | $182k 379,300 shares | +50% | |
| 51Moderate | ENSCbuy Ensysce Biosciences, Inc. | Bob G Gower director | $500k 357,143 shares | +90% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.